Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
13 hedge funds and large institutions have $918K invested in Oncobiologics, Inc. Series B Warrant in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$243K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$230K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$219K |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$123K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$65.8K |
Top Sellers
ONSIZ Hedge Fund Activity: Q2 2016 in Review
13 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q2 2016, worth a combined $918K.
Buyers outnumbered sellers: 13 funds opened new ONSIZ positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $243K.
- 13 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $918K of Oncobiologics, Inc. Series B Warrant stock for Q2 2016.
- 13 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q2 2016 and 0 closed out, a net change of +13 holders.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q2 2016 was Perceptive Advisors, an estimated $243K added.
Based on aggregated 13F filings for Q2 2016.